BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-karyopharm-xport-ec-042-mid2026-readout@catalyst-calendar.local
DTSTAMP:20260720T200622Z
DTSTART:20260701T130000Z
DTEND:20260701T133000Z
SUMMARY:Karyopharm XPORT-EC-042三期子宫内膜癌顶线数据窗口
DESCRIPTION:Karyopharm披露selinexor一线维持治疗子宫内膜癌XPORT-EC-042三期研究预计2026年中读出顶线数据；虽为单公司事件，但属三期肿瘤注册性读出，可能影响核输出抑制剂机制和妇科肿瘤维护治疗预期。\\nImpact score: 63\\nExpected: 顶线数据将决定selinexor在子宫内膜癌维持治疗中的注册路径和妇科肿瘤同类资产预期。\\nAffected: KPTI(subject\, unknown\, score 82)\; GSK(peer\, mixed\, score 45)\; MRK(peer\, mixed\, score 44)\; XBI(etf\, mixed\, score 50)\\nSources: Karyopharm Q1 2026 results and milestones: https://investors.karyopharm.com/2026-05-14-Karyopharm-Reports-First-Quarter-2026-Financial-Results-and-Completion-of-Phase-3-Endometrial-Cancer-Trial-Enrollment\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-karyopharm-xport-ec-042-mid2026-readout
CATEGORIES:guidance\,US\,clinical-readout\,Phase-3\,endometrial-cancer\,oncology
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Karyopharm XPORT-EC-042三期子宫内膜癌顶线数据窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Karyopharm XPORT-EC-042三期子宫内膜癌顶线数据窗口
END:VALARM
END:VEVENT
END:VCALENDAR